Interestingly, NRAS mutation of the primary tumor was present only in 6.9% of SLN-positive tumors, while it was detected in 20.8% of SLN-negative cases; however, this difference was not statistically significant either (Table 2). This evidence concerns the gene NRAS and neoplasm.